02196 FOSUN PHARMA
- 12.640
- +0.320+2.60%
FOSUN PHARMA News
Fosun Pharma's Q1 Profit Slumps 38%
Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196) posted a net profit attributable to owners of 609.7 million yuan in the first quarter of 2024, slumping 38.2% from 987 million yuan a year
Shanghai Fosun Pharmaceutical 1Q Net CNY609.73M Vs. Net CNY986.97M >0656.HK
Shanghai Fosun Pharmaceutical 1Q Net CNY609.73M Vs. Net CNY986.97M >0656.HK
復星醫藥：2024年第一季度報告
Fosun Pharmaceutical (02196): Fosun Pharmaceutical Industries and Kite Pharma plan to renew and provide additional loans totaling no more than 67 million US dollars to Fosun Kate based on their respective shareholding ratios
Fosun Pharmaceutical (02196) issued an announcement to satisfy Fosun Kate Biotechnology Co., Ltd. (hereinafter referred to as “Fosun Kate...
Fosun Pharmaceutical (02196, 600196.SH) 2024 Quarterly Report: Innovative achievements are being realized at an accelerated pace, and various new products are comprehensively advancing the commercialization process
During the reporting period, Fosun Pharmaceutical achieved revenue of 10.157 billion yuan, excluding COVID-related products, and achieved positive year-on-year growth in revenue. Net cash flow from operating activities was $917 million, up 5.05% year over year.
Zhitong Hong Kong Stock Investment Calendar | April 29
According to statistics from the Zhitong Finance App, on April 29, 2024, the investment log of Hong Kong stock listed companies is as follows: Category Company Performance Announcement Date: Bank of Zhengzhou Xinte Energy China Galaxy China Communications Construction Hyperion Fosun Pharmaceuticals CRRC Red Star Macalline Shanghai Electric Dongfang Electric Shareholders' Meeting Held Japan-China Guangzhou Nuclear Power Jilin Changlong Pharmaceutical Seaport Enterprise Delin International Asia Backup CLP Holdings Pacific Network China Building Materials Dividend Shenwei Pharmaceutical (excluding Clean Day) Comfort Project (dividend day) Chunquan Industrial Trust (dividend date) 361 degrees (excluding cleaning day) Prada (excluding clean day) ) Times Group Holdings (dividends)
Fosun Pharmaceutical (600196.SH): Cycloserine capsules approved for drug registration
Gelonghui, April 24 | Fosun Pharmaceutical (600196.SH) announced that the marketing registration application for cycloserine capsules (referred to as “the new drug”) independently developed by Shenyang Hongqi Pharmaceutical Co., Ltd., a holding subsidiary of the company, for the treatment of active tuberculosis and extrapulmonary tuberculosis (including renal tuberculosis) caused by tuberculosis bacteria sensitive to this drug and treated with first-line anti-tuberculosis drugs (such as streptomycin, isoniazid, rifampicin, and ethambutol) with poor treatment effects by first-line anti-tuberculosis drugs (such as streptomycin, isoniazid, rifampicin, and ethambutol), was recently approved by the State Drug Administration.
復星醫藥：二零二三年年報
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) Doing What It Can To Lift Shares
With a price-to-earnings (or "P/E") ratio of 25.5x Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) may be sending bullish signals at the moment, given that almost half of all companies i
A record high! Fosun Pharmaceutical (02196) was selected as one of the top 20 global pharmaceutical companies in terms of pipeline size
For the third year in a row, Fosun Pharmaceutical (02196) was selected as one of the top 25 pharmaceutical companies in the world, ranking 17th, up 7 places from the previous year.
Fosun Pharmaceutical (02196.HK): Investment funds participating in the establishment completed private equity fund filing
Gelonghui, April 22, 丨 Fosun Pharmaceutical (02196.HK) announced that on March 30, 2023, the company's holding subsidiary/enterprise Shanghai Fuyu Shengjian Enterprise Management Partnership (Limited Partnership) (hereinafter referred to as “Fuyu Shengjian”), Ningbo Fuying Investment Co., Ltd. (hereinafter referred to as “Ningbo Fuying”) and other 2 investors signed the “Anji Fuyu Chengxiang Venture Capital Partnership (Limited Partnership) Limited Partnership” with other investors to jointly fund the establishment of Anji Fucheng Yuxiang Venture Capital Partnership (Limited Partnership) “Equipment Fund”); same day, Company holding subsidiaries/corporate recovery
China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy
China's drug regulator granted clinical trial approval to a Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196) subsidiary for its HLX53 combination with slulimumab and bevacizumab injections
Fosun Pharmaceutical (02196.HK): Fuhong Hanlin was approved for drug clinical trials
Gelonghui, April 17 | Fosun Pharmaceutical (02196.HK) announced that the company's holding subsidiary Shanghai Fuhong Hanlin Biotechnology Co., Ltd. and its holding subsidiary (hereinafter collectively referred to as “Fuhong Hanlin”) recently received approval from the State Drug Administration to conduct clinical trials with HLX53 (i.e. anti-Tigit FC fusion protein) in combination with Hans form (i.e. slulizumab injection) and Hanbetai (i.e. bevacizumab injection) for first-line treatment of locally advanced or metastatic hepatocellular carcinoma (HCC). Fu Hong Hanlin plans to be in China after the conditions are met (excluding Hong Kong, Macao and Taiwan regions, below
Fosun Pharmaceutical (02196.HK) held a board meeting on April 29 to consider and approve the first quarter results
Gelonghui, April 17, 丨 Fosun Pharmaceutical (02196.HK) announced that it will hold a board meeting on April 29, 2024 (Monday) to consider, approve and publish the first quarter results of the company and its subsidiaries for the three months ended March 31, 2024.
復星醫藥：董事會會議日期
Fosun Pharmaceutical (600196.SH): Sodium phosphonate injection accepted for drug registration application
Gelonghui, April 17 | Fosun Pharmaceutical (600196.SH) announced that the drug registration application for sodium phosphonate injection from the holding subsidiary Guilin Southern Pharmaceutical Co., Ltd. was recently accepted by the State Drug Administration. This new pharmaceutical chemical is intended for use in (1) cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS); and (2) acyclovir-resistant herpes simplex virus (HSV) cutaneous mucosal infections in immunodeficiency patients.
Hong Kong Stock Concept Tracking | Novo Nordisk's new weight loss drug clinical approval industry in China will usher in a period of breakthrough results (with concept stocks)
On April 10, the official website of the Drug Evaluation Center of the State Drug Administration announced that the clinical trial application for Novo Nordisk's Class 1 new drug amycretin tablets was accepted.
Fosun Pharmaceutical (02196): Fuhong Hanlin plans to guarantee Hanlin Pharmaceuticals's financing debt with a principal amount not exceeding 150 million yuan from China Construction Bank
Fosun Pharmaceutical (02196) issued an announcement. On April 9, 2024, the company's holding subsidiary Shanghai Fuhong Hanlin Biotech...
China Accepts New Drug Applications for Fosun Pharma's Iron Overload Syndrome Drugs
China's medical products administrator accepted the new drug applications of Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) unit Fosun Pharmaceutical Industrial Development for the treatment of
Fosun Pharmaceutical (600196.SH): Holding subsidiary accepted drug registration application
Gelonghui, April 8, 丨 Fosun Pharmaceutical (600196.SH) announced that the registration application for drugs independently developed by the holding subsidiary Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. was recently accepted by the State Drug Administration.
Analysis
Price Target
No Data
